What Prolase Treats: Main Uses and Benefits

Prolase (Serrapeptase) is a systemic enzyme preparation considered relevant in contexts where supportive symptom management is appropriate, primarily for conditions involving inflammation and the resulting symptoms related to physical discomfort or viscous secretions. This agent is generally used across therapeutic domains where short-term symptomatic assistance is needed to contribute to easing the overall symptom load.

Reducing Swelling and Acute Discomfort After Trauma or Surgery

This is commonly used following minor surgical procedures, such as dental work, or after physical trauma. Applied in scenarios where additional management of discomfort is required, it contributes to improved comfort during periods of heightened symptoms in the recovery phase and may assist with maintaining functional stability.

Quick Fact: Relevant for Localized Swelling The medication is applied when short-term symptomatic assistance is needed for managing acute fluid accumulation (edema) in a specific area.

Symptomatic Support for Respiratory and Sinus Issues

The preparation is considered relevant across domains where additional symptomatic support is needed for conditions involving viscous mucus and phlegm buildup, as seen in sinusitis or bronchitis. It may assist with symptom clusters that may become disruptive, supporting the patient during difficult episodes by easing distress related to difficult secretion clearance.

Management of Localized Chronic Inflammatory Symptoms

Prolase may be part of symptomatic management for conditions characterized by periods of heightened symptoms of localized discomfort and stiffness. It helps maintain a sense of stability when symptoms are more noticeable and supports general well-being during symptomatic phases.

Regulatory References

1. Health Canada Natural Health Product Monograph on Serrapeptase

Eligibility Map: Who Can and Cannot Use Prolase — Official Regulatory Information

The eligibility profile for Prolase (Serrapeptase) is structured around official population-specific guidelines, primarily restricting use based on age, reproductive status, and conditions that affect blood clotting.

---

Eligibility Scope

Classification	Population Group	Regulatory Rule/Status
Allowed to Use	Adults (18 years and older)	Only population with documented use in monographs.
Contraindicated	Patients with known bleeding disorders	Use is contraindicated due to risk of increased bleeding.
	Patients scheduled for surgery	Must discontinue use at least 2 weeks prior to the procedure.
Not Recommended	Children and Adolescents (Under 18)	Use is not recommended; safety and efficacy are not established.
	Pregnant or Breastfeeding individuals	Use is not recommended due to lack of reliable safety data.

---

Eligibility-Related Restrictions

Restriction Context	Population Group	Official Requirement
Concurrent Medication	Patients taking Anticoagulants/Blood thinners	Consultation with a health professional is required before use.
Comorbidities	Individuals with kidney disorder or liver disorder	Consultation with a health professional is required before use.

---

Connection to the Overall Eligibility Profile

Official regulatory documents define Prolase eligibility by restricting its use to the adult population (18+) and establishing mandatory exclusions for individuals with pre-existing bleeding risks or scheduled surgery. Eligibility is further constrained by "not recommended" classifications for children and pregnant/breastfeeding individuals due to insufficient data, while specific organ disorders require professional consultation prior to use.

Interactions with other medicines and products

Official Pharmacodynamic Interaction Profile

The officially documented interaction profile for Prolase (Serrapeptase) is defined by its ability to slow blood clotting, creating a pharmacodynamic interaction when co-administered with other agents that affect coagulation. This is classified as a major interaction in regulatory documents.

Substance Category	Interaction Outcome	Administration Restriction
Anticoagulants and Antiplatelet Drugs	Additive effect, resulting in an increased risk of bleeding and bruising.	Mandatory cessation of Prolase is required at least 2 weeks before scheduled surgery.
Herbal Products and Supplements	Additive effect with products like Garlic, Fish Oil, or Turmeric that also slow blood clotting.	Co-administration should be avoided due to the enhanced risk of bleeding.

Timing and Population Notes

The additive effect mandates a specific timing-based restriction to prevent procedural bleeding risk. This restriction requires Prolase use to be stopped a minimum of two weeks prior to any planned surgical procedure. Regulatory cautions also advise consultation before use if the patient has a pre-existing kidney or liver disorder. No official regulatory documentation was found describing CYP-mediated metabolic or transporter-based interactions.

Proteolytic Debridement and Fluid Balance

Prolase (Serrapeptase) functions as a systemic extracellular metalloprotease, exerting a highly selective enzymatic action by breaking down non-viable protein aggregates and accumulated debris, such as fibrin, in the interstitial fluid. This targeted molecular clearance reduces the osmotic pressure exerted by these large molecules in the tissues. The resulting shift facilitates the reabsorption of excess fluid back into the lymphatic and vascular systems, resulting in the physiological consequence of decreased localized fluid volume.

---

Modulation of Inflammatory Mediators

The enzyme's mechanism also involves the degradation of key inflammatory peptides, notably bradykinin, which is a powerful mediator in the Kinin System that promotes both vascular permeability and pain signaling. By reducing the concentration of this mediator at the local site, the enzyme helps dampen the signaling that drives continued fluid leakage and nociceptive response. The resulting modulation of pain signaling provides a secondary physiological consequence alongside the primary fluid balance mechanism.

How to Use Prolase: Official Administration Guidelines

Prolase (Serrapeptase) is administered according to a specific protocol designed to ensure the delivery of the active enzyme for systemic effect.

---

Administration Protocol

The medicine is supplied as an enteric-coated tablet or capsule, which is formulated to prevent the enzyme from being deactivated by the stomach's acidic environment. This design dictates the required route and timing of administration.

Parameter	Official Administration Instruction
Route of Administration	Oral administration (by mouth).
Dosing Range	The standard adult daily dose is expressed in enzymatic activity units, ranging from 30,000 to 120,000 serratiopeptidase units (SU). The maximum daily intake is 120,000 SU.
Dosing Frequency	The total daily dose is typically administered in divided doses, commonly two or three times per day.
Timing Relative to Meals	Prolase must be taken on an empty stomach. This instruction specifies taking the dose approximately two hours after a meal or at least thirty minutes before eating.
Formulation Handling	The enteric-coated tablet or capsule must be swallowed whole and must not be crushed, chewed, or broken prior to ingestion.

---

Use Pattern Over Time

A limited duration of use is established, which depends on the administered dose. For higher daily regimens (up to 120,000 SU), administration is generally restricted to a maximum of seven days. For lower doses, the use period may extend up to four weeks. Dosing is specified only for adults 18 years and older, with no official guidance available for pediatric populations.

Research Evidence / Overview of Studies for Prolase

---

Evidence for Postoperative and Post-Trauma Swelling (Edema)

Prolase (Serrapeptase) was studied for its use in research exploring how symptoms change over time related to localized swelling and discomfort that can follow minor physical injury or surgical procedures, such as dental work. Researchers typically conducted short-term Randomized Controlled Trials (RCTs) to explore how symptoms change over time, monitoring objective changes in swelling and patient-reported pain/discomfort scores.

Some studies reported measurements where changes in swelling and discomfort were observed in the study populations compared to control groups. However, the evidence quality varies across studies, and the findings were mixed when Prolase was observed in trials that compared it to existing anti-inflammatory treatments. Research provides limited insight into how the observed patterns compare to standard anti-inflammatory medications. The follow-up durations were limited, typically lasting only a few days to one week.

---

Evidence for Symptomatic Support for Respiratory and Sinus Issues

Research has explored Prolase used in research contexts involving fluctuating or unstable symptoms in conditions involving viscous secretions, such as in cases of sinusitis or chronic bronchitis. The available research includes a limited number of RCTs. Researchers examined changes in the physical properties of mucus and monitored patient-reported outcomes describing perceived discomfort related to cough and nasal obstruction.

Because there are few high-quality, large-scale RCTs available for this use, the overall certainty remains low. The studies often focused on outcomes reflecting episodic or acute changes in symptoms over short-to-intermediate timeframes. Consequently, the research provides limited insight into long-term outcomes, such as sustained changes or patterns related to long-term use.

---

What Remains Unclear in the Research Record

Research provides context but not individual predictions regarding Prolase. A key research limitation is the modest sample sizes and short follow-up durations of many historical studies. More research is needed to fully characterize the specific circumstances and populations in which changes were observed in symptoms.

Key Studies & References

1. Serrapeptase Natural Health Product Monograph - Health Canada (2018/2025)
2. Randomized, double-blind, placebo-controlled clinical study of serratiopeptidase on postoperative swelling and pain after oral surgery (Tachibana et al. 1984)
3. Clinical evaluation of serratiopeptidase in the treatment of acute and chronic ENT disorders (Mazzone et al. 1990)

Common questions about Prolase (FAQ)

Q: How long does it usually take to feel the effects of Prolase?

A: Studies and official information indicate that the active ingredient reaches its peak level in the bloodstream approximately 15 to 30 minutes after taking the dose. This is known as the time to reach peak plasma concentration. The period of active presence in the blood is reported to be around six hours.

Q: Does Prolase cause weight gain or weight loss?

A: Official adverse reaction reports do not commonly list weight gain or weight loss as frequent side effects. However, the regulatory documentation includes gastrointestinal disturbances, which may involve a temporary loss of appetite.

Q: How is Prolase different from other similar treatments?

A: Prolase is distinct because its active ingredient is a systemic proteolytic enzyme that works by breaking down specific proteins like fibrin and inflammatory mediators (e.g., bradykinin). Regulatory-cited research notes that its overall action has been compared to the effects of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).

Q: What are the most common mild side effects reported for Prolase?

A: According to official product information, the most commonly reported mild adverse effects are typically gastrointestinal disturbances. These can include general stomach discomfort, nausea, vomiting, or diarrhea.

Q: Is it true that Prolase interacts with certain over-the-counter pain relievers?

A: Yes, regulatory documents state that Prolase can increase the risk of bruising and bleeding when used alongside other medications that slow blood clotting. This interaction specifically includes certain over-the-counter pain relievers, such as aspirin and ibuprofen.

Q: Can older adults (seniors) use Prolase safely?

A: Prolase is officially documented for use in adults 18 years and older only. However, official documentation states that individuals with pre-existing kidney or liver disorders must be evaluated by a healthcare professional prior to use.

Q: What is the risk of dependence or withdrawal with Prolase?

A: The active ingredient in Prolase is a systemic enzyme and is not classified as a controlled substance by regulatory bodies. Official product information contains no mention of the potential for dependence or a standard drug withdrawal syndrome.

Q: Is Prolase considered a narcotic or controlled substance?

A: No. According to regulatory classification systems, the active ingredient Serrapeptase is not considered a narcotic or a controlled substance. It is categorized as a systemic enzyme preparation.

Q: Why do people sometimes stop taking Prolase?

A: Regulatory documentation requires discontinuation and consultation with a healthcare professional if symptoms persist or worsen. Discontinuation is also required if signs of serious known adverse reactions, such as rash or severe allergy, occur.

Q: What should I do if a side effect of Prolase bothers me?

A: Official regulatory guidance states that consultation with a healthcare professional is necessary if symptoms or side effects persist or worsen during administration. This allows for proper evaluation of the reaction and next steps.

Q: How long does Prolase stay in your system after stopping it?

A: Studies examining the pharmacokinetics of the medicine report that the active enzyme has a biological half-life of approximately one to four hours. The half-life describes the time it takes for the amount of medicine in the body to be reduced by half.

Q: Are allergic reactions to Prolase common?

A: Regulatory warnings note that hypersensitivity (allergic reactions) has been known to occur. Official warnings state that the medicine should be discontinued if signs of a severe allergy, such as a rash or difficulty breathing, are experienced.

Q: Is the mechanism of action of Prolase fully understood?

A: The core mechanism of Prolase as an enzyme that breaks down proteins is well-defined in official literature. However, research indicates that the exact details of how the large enzyme molecule is absorbed from the digestive system into the bloodstream are still a topic of scientific investigation.

Q: Does Prolase come in different strengths?

A: Official dosing documentation shows that the medicine is administered in a wide range of units (up to 120,000 SU). This range means the medicine is typically supplied in various tablet or capsule strengths, corresponding to different prescribed daily amounts.

Q: Is it normal to feel a change in appetite when starting Prolase?

A: Loss of appetite is listed in regulatory summaries as one of the documented gastrointestinal disturbances that may occur while using the medicine. This is included under the general category of adverse events.

Q: Are there different brand names for the medicine Prolase?

A: Yes, regulatory databases and official product licence information indicate that the active ingredient Serrapeptase is sold under various brand names and formulations globally. This includes formulations regulated as Natural Health Products in some regions.

Q: How does Prolase compare to its competitors in terms of how it works?

A: The mechanism of Prolase is distinct because it is an enzyme that directly targets and breaks down specific proteins related to swelling. Research has noted that this action may produce effects that are in some ways similar to the effects of common anti-inflammatory drugs (COX-1 and COX-2 inhibitors).

Official Storage and Disposal Requirements

The storage requirements for Prolase (Serrapeptase) are designed to protect the stability of the enzyme formulation, according to official regulatory guidelines.

Item	Requirement
Temperature & Environment	Store in a cool, dry place and avoid exposure to heat or high humidity. The product must be protected from direct sunlight and temperatures above 25 C.
Container & Protection	Keep the container tightly closed and in its original, light-resistant packaging to prevent moisture and air exposure.
Child Safety	The medicine must be kept out of the sight and reach of children.
Disposal	Dispose of unused or expired Prolase according to local and national regulations for pharmaceutical waste. Do not flush the medicine down the toilet or throw it into any wastewater system.